Explore the latest in peripheral arterial disease, including diagnosis, prevention, and management of the disease and its risk factors.
This analysis of data from the EUCLID trial characterizes the incidence and types of myocardial infarction in patients with peripheral artery disease, identifies factors associated with myocardial infarction, and determines the association of myocardial infarction with cardiovascular mortality and acute limb ischemia.
This population-based cohort study evaluates whether ankle-brachial indices identified through electronic health records among community-dwelling patients with peripheral artery disease are associated with limb revascularization or amputation.
This secondary analysis of the Examining Use of Ticagrelor in Peripheral Artery Disease (EUCLID) trial examines the risk of ischemic events in patients with peripheral artery disease (PAD) and polyvascular disease (PAD with coronary artery disease [CAD] and/or cerebrovascular disease [CVD]).
This population-based cohort study of commercially insured patients examines the association between use of oral medication for type 2 diabetes and lower extremity amputation, peripheral arterial disease, critical limb ischemia, osteomyelitis, and ulcer.
This JAMA Patient Page describes the US Preventive Services Task Force recommendations on screening for peripheral artery disease with measurement of the ankle-brachial index.
This systematic review to support the 2018 US Preventive Services Task Force Recommendation Statement on screening for peripheral artery disease (PAD) using the ankle-brachial index (ABI) summarizes published evidence on the diagnostic accuracy of the ABI test and the benefits and harms of treatment of screen-detected PAD.
This 2018 Recommendation Statement from the US Preventive Services Task Force concludes that current evidence is insufficient to assess the balance of benefits and harms of screening for peripheral artery disease and cardiovascular disease risk with the ankle-brachial index in asymptomatic adults (I statement).
This JAMA Clinical Update reviews CVD risk stratification of patients with peripheral artery disease (PAD) and current standards of practice for use of antiplatelet and anticoagulant therapies.
This randomized controlled trial compares the effect of a 9-month home-based exercise intervention comprising a wearable activity monitor and telephone coaching vs usual care on 6-minute walk distance among patients with peripheral artery disease.
This cohort study uses claims data from Taiwan’s National Health Insurance program to investigate associations between varicose veins and risk of deep venous thrombosis (DVT), pulmonary embolism (PE), and peripheral artery disease (PAD).
This study explores the frequency of intracranial atherosclerotic disease in patients who have had a stroke and whether it coexists with systemic atherosclerotic lesions and other stroke etiologies.
This 2 × 2 factorial trial compared the effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) vs placebo and of supervised treadmill exercise vs education control on 6-minute walk distance at 12 weeks in patients with peripheral artery disease.
This randomized clinical trial reports the effect of a daily dose of resveratrol vs placebo on the walking ability and endurance of older people with peripheral artery disease.
This Viewpoint reviews treatment options to improve walking ability and quality of life for patients with lower extremity peripheral artery disease.
This narrative review summarizes recent advances in understanding the epidemiology, pathophysiology, diagnosis, and treatment of critical limb ischemia.
This cohort study compares clinical outcomes of patients with intermittent claudication and peripheral arterial disease treated with revascularization vs medical treatment.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: